---
title: "Portage Biotech reports $6.8 million net loss in fiscal year 2025, a significant decrease from $75.4 million in fiscal year 2024. Expenses decreased in R&D and G&A categories. Company had $1.7 million in cash with $1.1 million in total current liabilities as of March 31, 2025."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/250205684.md"
description: "Portage Biotech Inc. reported a net loss of $6.8 million for the fiscal year ending March 31, 2025, a significant reduction from $75.4 million in 2024. Operating expenses fell to $7.4 million, driven by a $9.4 million decrease in R&D costs and a $1.4 million reduction in G&A expenses. As of March 31, 2025, the company had $1.7 million in cash and $1.1 million in current liabilities, while focusing on advancing its immuno-oncology biologics pipeline."
datetime: "2025-07-25T20:44:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250205684.md)
  - [en](https://longbridge.com/en/news/250205684.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250205684.md)
generator: "portal-rs"
---

# Portage Biotech reports $6.8 million net loss in fiscal year 2025, a significant decrease from $75.4 million in fiscal year 2024. Expenses decreased in R&D and G&A categories. Company had $1.7 million in cash with $1.1 million in total current liabilities as of March 31, 2025.

Portage Biotech Inc. reported its financial results for the fiscal year ended March 31, 2025. They incurred a net loss of approximately $6.8 million, down significantly from the previous year's loss of $75.4 million. Operating expenses decreased to $7.4 million in 2025 from $18.2 million in 2024, with R&D expenses dropping by approximately $9.4 million primarily due to lower clinical trial costs. G&A expenses also decreased by $1.4 million. The Company had cash and cash equivalents of approximately $1.7 million and total current liabilities of about $1.1 million as of March 31, 2025. The Company is focused on advancing a pipeline of novel biologics for immuno-oncology. Risk factors and forward-looking statements are included in their disclosure.

### Related Stocks

- [PRTG.US](https://longbridge.com/en/quote/PRTG.US.md)

## Related News & Research

- [07:30 ETPackGene to Present Advances in Scalable AAV Manufacturing, Analytical Innovation, and Novel Capsid Engineering at ASGCT 2026](https://longbridge.com/en/news/285198584.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**